Online citations, reference lists, and bibliographies.
← Back to Search

Therapeutic Effects Of Tacrolimus Ointment For Refractory Ocular Surface Inflammatory Diseases.

D. Miyazaki, T. Tominaga, Akiko Kakimaru-Hasegawa, Yuiko Nagata, J. Hasegawa, Y. Inoue
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE To investigate the therapeutic effects of topical tacrolimus ointment on refractory ocular surface inflammatory diseases. DESIGN Retrospective interventional consecutive case series. PARTICIPANTS Ten consecutive patients with severe ocular surface inflammatory diseases who were suspected to be steroid responders (elevation of intraocular pressure [IOP]) or were refractory to standard steroid therapy were studied. One patient had peripheral ulcerative keratitis with impending corneal perforation, 1 had a Mooren's ulcer, 2 had scleroperikeratitis, 5 had atopic keratoconjunctivitis, and 1 had vernal keratoconjunctivitis. METHODS The clinical findings and therapeutic responses after treatment with 0.02% topical tacrolimus ointment were determined by conventional ophthalmological examinations. MAIN OUTCOME MEASURES Resolution of the ocular surface diseases (e.g., decrease of hyperemia, ulceration, size of papillae) and IOP. The necessity to use steroids was also assessed. RESULTS In all cases, marked to moderate improvement was obtained, including suppression of the melting reaction of the inflamed cornea, remission of scleroperikeratitis, and reduction of a giant papilla and corneal epithelial defect in severe atopic keratoconjunctivitis. The elevated IOP was reduced in steroid responders after successful cessation of steroid therapy. No adverse side effect was noted for 2 to 26 months of continuous treatment. CONCLUSIONS Topical tacrolimus ointment is effective in treating refractory ocular surface inflammatory diseases and should be considered as an alternative to higher doses, steroid supplementation, or surgical intervention.
This paper references
10.1016/J.JACI.2003.10.065
Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment.
P. Vichyanond (2004)
10.1038/35001102
How self-tolerance and the immunosuppressive drug FK506 prevent B-cell mitogenesis
R. Glynne (2000)
10.1067/MJD.2001.109810
Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy.
J. Hanifin (2001)
10.7164/ANTIBIOTICS.40.1249
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.
Toru Kino (1987)
10.1016/S0151-9638(06)70869-9
Traitement d'une localisation oculaire de pemphigoïde cicatricielle par tacrolimus topique
J. Michel (2006)
[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits].
Wen-lei Fei (2006)
10.1007/BF01973261
Biological effects of cyclosporin A: A new antilymphocytic agent
J. Borel (2005)
10.1038/sj.bjp.0707002
Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506
C. Harrison (2007)
10.1097/01.ico.0000114836.13127.45
The Relation of Conjunctival and Corneal Findings in Severe Ocular Allergies
M. Tanaka (2004)
10.1097/01.ico.0000127484.46584.f6
Treatment of Atopic Eyelid Disease Using Topical Tacrolimus Following Corticosteroid Discontinuation in a Patient With Open-Angle Glaucoma
G. Kymionis (2004)
Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders.
A. Cheng (2006)
10.2174/0929867043455576
Inhibitors of the calcineurin/NFAT pathway.
S. Martı́nez-Martı́nez (2004)
10.1111/J.1600-0420.2006.00699.X
Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study.
Hannele M Virtanen (2006)
10.1002/14651858.CD005161.PUB2
Cyclosporin versus tacrolimus for liver transplanted patients.
E. Haddad (2006)
[Topical tacrolimus treatment for ocular cicatricial pemphigoid].
J. Michel (2006)
10.1016/S0161-6420(91)32272-3
Long-term results of keratoepithelioplasty in Mooren's ulcer.
S. Kinoshita (1991)
10.1111/j.1432-2277.2004.00006.x
Topical FK506 as immunoprophylaxis after allogeneic penetrating normal‐risk keratoplasty: a randomized clinical pilot study
T. Reinhard (2005)
10.2165/00044011-200626050-00001
Comparison of the Efficacy and Safety of 0.1% Tacrolimus Ointment with Topical Corticosteroids in Adult Patients with Atopic Dermatitis
H. Nakagawa (2006)
10.1016/S0002-9394(02)01982-7
Topical tacrolimus treatment of atopic eyelid disease.
Sarah M Rikkers (2003)
10.1055/S-2001-18665
[FK 506 ointment 0.1 % - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients].
K. Mayer (2001)
10.1111/j.1600-6143.2006.01360.x
Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis
Vivian Charles McAlister (2006)
10.1007/BF00173216
The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line
M. Schwaninger (2004)
10.1067/MJD.2001.109817
Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.
N. Soter (2001)



This paper is referenced by
Efficacy of Topical Tacrolimus 0.05% Suspension on Treatment of Steroid Resistant Refractory Vernal Keratoconjunctivitis
A. B. Rafii (2013)
10.4103/0974-9233.164616
Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis
A. Al-Amri (2016)
10.1016/j.sjopt.2019.04.001
Therapeutic effects of topical 0.03% Tacrolimus ointment in children with refractory vernal keratoconjunctivitis in Middle East
Sandra Flavia Fiorentini (2019)
10.1097/ICO.0b013e3181d83875
Topical Tacrolimus Ointment for Treatment of Intractable Atopic Keratoconjunctivitis: A Case Report and Review of the Literature
D. P. García (2011)
10.4103/ojo.OJO_232_2014
Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis
A. Al-Amri (2017)
10.1038/bmt.2009.249
Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD
P. Tam (2010)
10.1016/j.survophthal.2011.06.003
Management of corneal perforation.
V. Jhanji (2011)
10.1016/J.OFTAL.2016.03.017
Tacrolimus tópico al 0,03% en el tratamiento de la psoriasis ocular
Paz Rodríguez-Ausín (2016)
10.1016/j.ajo.2014.11.035
Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease.
J. W. Jung (2015)
10.1007/s40267-019-00694-w
Act quickly when treating atopic keratoconjunctivitis to avoid adverse outcomes
Adis Medical Writers (2020)
10.1097/ICO.0000000000001440
Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis
Chang Ho Yoon (2018)
10.1007/s00417-019-04287-1
Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis
F. Liu (2019)
10.13005/BBRA/2088
Topical and Oral Cyclosporine for a Case of Severe Limbal Vernal Keratoconjunctivitis with Complete Corneal Involvement
Norah Alkheraiji (2016)
Conjunctival mast cell as a mediator of eosinophilic response in ocular allergy
D. Miyazaki (2008)
10.3390/ph13110351
Nanotechnology for the Treatment of Allergic Conjunctival Diseases
Y. Liu (2020)
Table 2 : Grading Scale Of Clinical Symptoms Symptom Score Severity Itching
Dr. Jitendra Kumar (2017)
10.1097/ICL.0b013e3181b4d135
Topical Cyclosporine A as a Steroid-Sparing Agent in Steroid-Dependent Idiopathic Ocular Myositis With Scleritis: A Case Report and Review of the Literature
K. Gumus (2009)
10.5935/0004-2749.20170038
Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial.
E. G. Müller (2017)
10.5935/0004-2749.20170052
Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children.
Vera Lucia Liendo (2017)
10.1016/S1130-6343(09)70998-5
Pomada oftálmica de tacrolimus para el tratamiento de úlceras corneales inmunológicas
C. Dávila-Fajardo (2009)
10.1089/jop.2011.0143
Treatment of refractory atopic blepharoconjunctivitis with topical tacrolimus 0.03% dermatologic ointment.
Y. Sakarya (2012)
10.1016/J.OFTALE.2016.06.010
Topical tacrolimus 0.03% for the treatment of ocular psoriasis.
P. Rodríguez-Ausín (2016)
10.1016/j.clae.2009.08.002
The management of allergic eye diseases in primary eye care.
Degaulle I Chigbu (2009)
10.1272/jnms.83.31
Therapeutic Effect of 0.1% Topical Tacrolimus for Childhood Interstitial Keratitis Refractory to Cyclosporine.
T. Joko (2016)
10.1097/ACI.0000000000000089
Topical immunomodulators in the management of allergic eye diseases
N. Erdinest (2014)
10.1016/B978-0-323-06387-6.00099-4
Corneal Disease in Rheumatoid Arthritis
Vanee V Virasch (2011)
10.1136/bjo.2009.165316
Basophils in the giant papillae of chronic allergic keratoconjunctivitis
A. Matsuda (2009)
10.1007/s10384-020-00774-9
Reduced steroid-induced intraocular pressure elevation in tacrolimus-treated refractory allergic ocular diseases
D. Miyazaki (2020)
10.1016/j.ophtha.2018.10.020
Conjunctivitis Preferred Practice Pattern®.
Divya M. Varu (2019)
10.1586/eop.10.43
Mechanisms of corneal allergic reaction: new options for treatment
A. Leonardi (2010)
10.1007/s10384-018-0600-y
Clinical characteristics and ocular complications of patients with scleritis in Japanese
Rie Tanaka (2018)
10.1007/978-3-540-85544-6_8
Allergic Disease of the Conjunctiva and Cornea
A. Leonardi (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar